{
    "clinical_study": {
        "@rank": "25232", 
        "arm_group": [
            {
                "arm_group_label": "L. reuteri", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Identical Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find whether Lactobacillus reuteri prevents\n      antibiotic-associated diarrhea and related Clostridium difficile infections. Subjects will\n      be admitted from the University Hospitals Case Medical Center. They will be randomly\n      assigned to an intervention group receiving L. reuteri or a placebo. Supplementation will\n      occur during antibiotic treatment and for an additional 7 days after cessation of treatment.\n      Data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic\n      cessation, and 21 days after antibiotic cessation. Primary data includes diarrhea instances.\n      Secondary data includes severity of diarrhea, presence of C. difficile toxins, and presence\n      of other GI symptoms."
        }, 
        "brief_title": "Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Antibiotic-associated Diarrhea", 
            "Clostridium Difficile"
        ], 
        "condition_browse": {
            "mesh_term": "Diarrhea"
        }, 
        "detailed_description": {
            "textblock": "The data being measured for this study include:\n\n      Primary outcome = incidence of diarrhea during and after treatment with antibiotics. An\n      episode of diarrhea is defined as the discrete period between the time when stool output\n      meets or exceeds three soft and unformed or watery bowel movements to the time when formed\n      stools return, which must be at least 48 hours later.\n\n      Secondary variables:\n\n        1. severity of diarrhea measured as the discrete period between the time when stool output\n           meets or exceeds 3 soft and unformed or watery bowel movements to the time when formed\n           stools return.\n\n        2. frequency of stool samples positive for C. Difficile toxin A or B at baseline, when\n           presenting with diarrhea during the study period, and at the follow-up 21 days\n           post-antibiotic-treatment to detect possible clearance of C. Difficile, in patients\n           ingesting L. reuteri versus placebo.\n\n        3. frequencies of other gastrointestinal symptoms at 1, 2, and 4 weeks, in the L. reuteri\n           group versus placebo and assessed by the validated Gastrointestinal Symptom Rating\n           Score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Receiving antibiotics for not more than 48 hours prior to enrollment and free from\n             diarrhea\n\n          -  able to understand and sign informed consent and HIPPA\n\n          -  available throughout the study period\n\n          -  subjects should have the mental ability to understand and willingness to fulfill all\n             the details of the protocol\n\n        Exclusion Criteria:\n\n          -  three or more soft and unformed or watery stools per day at admission\n\n          -  receiving chemotherapy or radiation therapy\n\n          -  diagnosis of inflammatory bowel disease\n\n          -  NPO without PO meds\n\n          -  neutropenia (an absolute neutrophil count (ANC) of less than 1500/microL)\n\n          -  HIV positive with a CD4+ T-lymphocyte count <400 per mcL blood\n\n          -  requiring care in an intensive care unit\n\n          -  status-post bowel resection during hospitalization\n\n          -  patient's receiving antibiotics four weeks prior to hospitalization\n\n          -  patient with severe life threatening illness or immunocompromised\n\n          -  pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 23, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127814", 
            "org_study_id": "RES504803"
        }, 
        "intervention": {
            "arm_group_label": [
                "L. reuteri", 
                "Identical Placebo"
            ], 
            "description": "One chewable tablet of 1E8 CFU L. reuteri, once per day", 
            "intervention_name": "Lactobacillus reuteri", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "BioGaia, Probiotic Chewable Tablets"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "induced diarrhea", 
            "Clostridium difficile toxicity"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106"
                }, 
                "name": "University Hospitals Case Medical Center"
            }, 
            "investigator": {
                "last_name": "Alison L Steiber, PhD,RD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of the Probiotic Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile Related Infections in Hospitalized Adult Patients", 
        "overall_contact": {
            "email": "als25@case.edu", 
            "last_name": "Alison L Steiber, PhD, RD,", 
            "phone": "216-368-2075"
        }, 
        "overall_official": {
            "affiliation": "Case Western Reserve University", 
            "last_name": "Alison L Steiber, PhD, RD, LD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Instances of diarrhea", 
            "measure": "diarrhea", 
            "safety_issue": "Yes", 
            "time_frame": "28+ days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127814"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Case Western Reserve University", 
            "investigator_full_name": "Alison Steiber", 
            "investigator_title": "Adjunct profession", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "measured as the discrete period between the time when stool output meets or exceeds three soft and unformed or watery bowel movements to the time when formed stools return.", 
                "measure": "Severity of diarrhea", 
                "safety_issue": "No", 
                "time_frame": "28+ days"
            }, 
            {
                "description": "Frequency of stool samples positive for C. difficile toxin A and B at baseline, when presenting with diarrhea during the study period, and at the follow-up 21 days post antibiotic-treatment to detect possible clearance of C. difficile, in patients ingesting L. reuteri versus placebo.", 
                "measure": "Frequency of stool samples positive for C. difficile toxin A and B", 
                "safety_issue": "No", 
                "time_frame": "baseline, when presenting with diarrhea during the study period, and at the follow-up 21 days"
            }, 
            {
                "description": "Frequencies of other gastrointestinal symptoms at 1, 2 and 4 weeks, in the L. reuteri group versus placebo and assessed by the validated GSRS score (Gastrointestinal Symptom Rating Score).", 
                "measure": "Frequencies of other gastrointestinal symptoms", 
                "safety_issue": "No", 
                "time_frame": "1, 2 and 4 weeks"
            }
        ], 
        "source": "Case Western Reserve University", 
        "sponsors": {
            "collaborator": {
                "agency": "BioGaia AB", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Case Western Reserve University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}